$0.70−0.05 (−6.48%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD
Allogene Therapeutics (ALLO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
12 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 100% below its peak (through FY24), net margin −1170863.6%. Worth your attention in FY25: Share count (+62.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲25.9%
−190.9
FY21→FY25CAGR —
Free cash flow ($M)▲25.6%
−149.6
FY21→FY25CAGR —
Diluted EPS▲34.1%
−0.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+62.4%
135.8mn → 220.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$386.0K
−44.4% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Operating Net
This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6375, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 4,640.0 | 0.0 | 22.0 | 95.0 | 156.0 | 114,089.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | 0.0 | —A | —A | —A | —A | — | — |
Research & development | 133,290.0 | 150,152.0 | 192,299.0 | 242,914.0 | 256,387.0 | 220,176.0 | ▼21.9% | −9.1% |
Selling, general & admin | 61,559.0 | 56,781.0 | 65,205.0 | 71,673.0 | 79,305.0 | 74,105.0 | ▼12.9% | −6.4% |
Total operating expenses | 194,849.0 | 209,315.0 | 273,221.0 | 327,832.0 | 335,692.0 | 294,281.0 | ▼23.4% | −8.2% |
Operating incomefeeds ROC rank | −190,209.0 | −209,315.0 | −273,199.0 | −327,737.0 | −335,536.0 | −180,192.0 | ▲23.4% | — |
Other income, net | 15,746.0 | 18,429.0 | 16,052.0 | 472.0 | −4,878.0 | −1,859.0 | — | — |
Pretax income | −174,463.0 | −190,886.0 | −257,147.0 | −327,265.0 | −340,414.0 | −182,051.0 | ▲25.8% | — |
Income tax | — | 0.0 | 443.0 | 0.0 | — | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −174,463.0 | −190,886.0 | −257,590.0 | −327,265.0 | −340,414.0 | −182,051.0 | ▲25.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.63 | −0.87 | −1.32 | −2.09 | −2.38 | −1.34 | ▲34.1% | — |
Diluted shares (mn) | 346.09 | 220.62 | 194.81 | 156.93 | 143.15 | 135.82 | ▲13.2% | +12.9% |
| Margins | ||||||||
Gross margin | —A | — | —A | —A | —A | —A | — | — |
Operating margin | −4099.3% | — | −1241813.6% | −344986.3% | −215087.2% | −157.9% | — | — |
Net margin | −3760.0% | — | −1170863.6% | −344489.5% | −218214.1% | −159.6% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

